Literature DB >> 29600025

Cardiovascular events after discontinuation of low-dose aspirin.

Manan Pareek1,2, Steen D Kristensen2,3, Erik L Grove2,3.   

Abstract

Entities:  

Year:  2018        PMID： 29600025      PMCID： PMC5863118          DOI： 10.21037/jtd.2017.12.48

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  25 in total

1.  Non-adherence to cardiovascular medications.

Authors:  Kumaran Kolandaivelu; Benjamin B Leiden; Patrick T O'Gara; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2014-09-28       Impact factor: 29.983

2.  Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.

Authors:  Kristian H Christensen; Erik L Grove; Morten Würtz; Steen D Kristensen; Anne-Mette Hvas
Journal:  Platelets       Date:  2014-04-21       Impact factor: 3.862

Review 3.  Reasons for intentional guideline non-adherence: A systematic review.

Authors:  Derk L Arts; Albertine G Voncken; Stephanie Medlock; Ameen Abu-Hanna; Henk C P M van Weert
Journal:  Int J Med Inform       Date:  2016-02-23       Impact factor: 4.046

4.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Authors:  John W Eikelboom; Stuart J Connolly; Jackie Bosch; Gilles R Dagenais; Robert G Hart; Olga Shestakovska; Rafael Diaz; Marco Alings; Eva M Lonn; Sonia S Anand; Petr Widimsky; Masatsugu Hori; Alvaro Avezum; Leopoldo S Piegas; Kelley R H Branch; Jeffrey Probstfield; Deepak L Bhatt; Jun Zhu; Yan Liang; Aldo P Maggioni; Patricio Lopez-Jaramillo; Martin O'Donnell; Ajay K Kakkar; Keith A A Fox; Alexander N Parkhomenko; Georg Ertl; Stefan Störk; Matyas Keltai; Lars Ryden; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek J Guzik; Peter B Verhamme; Dragos Vinereanu; Jae-Hyung Kim; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; P Gabriel Steg; Kaj P Metsarinne; Nancy Cook Bruns; Frank Misselwitz; Edmond Chen; Darryl Leong; Salim Yusuf
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

5.  Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR).

Authors:  Hurst M Hall; James A de Lemos; Jonathan R Enriquez; Darren K McGuire; S Andrew Peng; Karen P Alexander; Matthew T Roe; Nihar Desai; Stephen D Wiviott; Sandeep R Das
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-08-12

6.  Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.

Authors:  E Magnus Ohman; Matthew T Roe; P Gabriel Steg; Stefan K James; Thomas J Povsic; Jennifer White; Frank Rockhold; Alexei Plotnikov; Hardi Mundl; John Strony; Xiang Sun; Steen Husted; Michal Tendera; Gilles Montalescot; M Cecilia Bahit; Diego Ardissino; Héctor Bueno; Marc J Claeys; Jose C Nicolau; Jan H Cornel; Shinya Goto; Róbert Gábor Kiss; Ümit Güray; Duk-Woo Park; Christoph Bode; Robert C Welsh; C Michael Gibson
Journal:  Lancet       Date:  2017-03-18       Impact factor: 79.321

7.  Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.

Authors:  Jennifer Yu; Roxana Mehran; George D Dangas; Bimmer E Claessen; Usman Baber; Ke Xu; Helen Parise; Martin Fahy; Alexandra J Lansky; Bernhard Witzenbichler; Cindy L Grines; Giulio Guagliumi; Ran Kornowski; Jochen Wöhrle; Dariusz Dudek; Giora Weisz; Gregg W Stone
Journal:  JACC Cardiovasc Interv       Date:  2012-12       Impact factor: 11.195

8.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).

Authors:  Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský
Journal:  Eur Heart J       Date:  2018-01-07       Impact factor: 29.983

9.  2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno
Journal:  Eur Heart J       Date:  2016-05-23       Impact factor: 29.983

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.